2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics Inc. (TGTX) based on the data you provided, presented in a clear and structured manner.

**1) Return Rate Comparison (TGTX vs. S&P 500 (VOO))**

*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 72.74%
*   **VOO (S&P 500) Cumulative Return:** 91.40%
*   **Divergence:** -32.3
*   **Relative Divergence:** 15.5

**Analysis:** TGTX has underperformed the S&P 500 over the observed period. The divergence of -32.3 indicates a significant difference in cumulative returns. The relative divergence of 15.5 suggests that the current divergence is closer to the minimum end of its historical fluctuation range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta | Cap(B) |
|------------|--------|-------|---------|------|--------|
| 2016-2018  | -51.0% | 99.5% | -55.0% | 1.8 | 0.7    |
| 2017-2019  | 71.0%  | 99.9% | 54.0%  | 1.8 | 1.8    |
| 2018-2020  | 332.0% | 99.8% | 311.0% | 1.6 | 8.3    |
| 2019-2021  | 130.0% | 94.6% | 86.0%  | 1.6 | 3.0    |
| 2020-2022  | -86.0% | 100.0% | -84.0% | 1.9 | 1.9    |
| 2021-2023  | -315.0% | 100.0% | -316.0% | 2.4 | 2.7    |
| 2022-2024  | 57.0%  | 98.9% | 38.0%  | 2.3 | 4.8    |
| 2023-2025  | 67.0%  | 98.0% | 4.0%  | 1.1 | 4.7    |

*   **CAGR (Compound Annual Growth Rate):**  Highly volatile, ranging from significant losses to substantial gains depending on the period. Recent years show positive growth, but less impressive than 2018-2020.
*   **MDD (Maximum Drawdown):**  Consistently high (near 100%), indicating substantial risk and price volatility.  This means the stock has experienced significant drops from peak to trough in all periods.
*   **Alpha:** Fluctuates wildly, suggesting that TGTX's performance is heavily influenced by company-specific factors rather than broader market trends. A negative alpha indicates underperformance relative to the market, while a positive alpha indicates outperformance.
*   **Beta:** Consistently above 1, indicating that TGTX is more volatile than the market.  The recent decrease to 1.1 suggests reduced volatility compared to earlier periods.
*   **Cap(B) (Capitalization in Billions):** Shows the company's market capitalization fluctuating over the periods, reflecting changes in investor sentiment and company performance.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 29.81
*   **Previous Close:** 29.75
*   **Change:** 0.2
*   **5-day SMA:** 30.39
*   **20-day SMA:** 30.85
*   **60-day SMA:** 32.39

**Analysis:** The stock price is slightly up in the most recent session.  The SMAs indicate a downward trend, as the shorter-term averages are below the longer-term average. This suggests recent price weakness.

**3) Market Risk Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 44.78
*   **PPO (Percentage Price Oscillator):** -0.189
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (31 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.8 (단기하락 - short-term decline)
*   **Expected Return (%):** 0.0%

**Analysis:**

*   **MRI:** Suggests a medium level of risk, but still leaning towards higher investment recommendation.
*   **RSI:** Indicates the stock is neither overbought nor oversold.
*   **PPO:** A slightly negative PPO suggests a slight downward trend in price momentum.
*   **Hybrid Signal:** This signal is advising to invest 100% of available cash into the stock, citing "Very Safe" based on the MRI. However, this contradicts other indicators showing recent short-term decline.
*   **Divergence Change:** Confirms the recent downward trend.
*   **Expected Return:** A 0% expected return suggests that, based on current analysis, no significant outperformance is anticipated compared to the S&P 500 over a long-term investment.

**4) Recent News & Significant Events**

*   **Mixed Headlines:** The news articles present a mixed picture. Some suggest potential undervaluation ("Could The Market Be Wrong"), while others point to weaknesses ("Stock Has Shown Weakness"). One article highlights an earnings caveat leading to a stock dive ("The Earnings Caveat That Sent This Hot Biotech Diving").
*   **Wall Street Sentiment:** One article suggests Wall Street may not be fully appreciating TGTX ("What Wall Street Isn't Telling You").
*   **Analyst Coverage:** Mentions a Q3 results call and business update.
*   **Past Performance:** One article highlights a 160% gain over three years, though this may not be indicative of future performance.

**4-2) Analyst Opinions**

*   **Consensus:** Neutral (no strong buy or sell consensus)
*   **Target Price:** Average target of $44.29, with a wide range ($13 - $60). This wide range indicates uncertainty and differing opinions among analysts.
*   **Recent Rating Changes:** No recent rating changes are provided, suggesting stable analyst views.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-05 | 2.69 | 0.16 B$ |
| 2025-08-08 | 0.19 | 0.14 B$ |
| 2025-05-09 | 0.03 | 0.12 B$ |
| 2024-11-07 | 0.03 | 0.08 B$ |
| 2025-11-05 | 0.03 | 0.08 B$ |

**Analysis:**

*   **EPS (Earnings Per Share):**  EPS shows huge increase (2.69) in the most recent quarter (2025-11-05), though earnings were low in the recent year.
*   **Revenue (매출):** Revenue has been generally increasing over the past few quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $0.61B    | 64.37%    |
| 2025-06-30   | $0.28B    | 10.20%    |
| 2025-03-31   | $0.24B    | 2.13%     |
| 2024-12-31   | $0.22B    | 10.49%    |
| 2024-09-30   | $0.19B    | 2.02%     |

**Analysis:**

*   **Revenue:** Consistent growth in revenue over the past year is positive.
*   **Profit Margin:**  Very high profit margins indicate strong operational efficiency and pricing power, though fluctuations should be monitored.
*   **Equity:** Increasing equity suggests the company is building a stronger financial foundation.
*   **ROE (Return on Equity):** The very high ROE in the latest quarter (64.37%) is a strong indicator of profitability and efficient use of shareholder equity. However, the fluctuations in ROE indicate volatility.

**7) Comprehensive Analysis (Summary)**

TG Therapeutics Inc. (TGTX) presents a mixed investment picture.

*   **Positives:**
    *   Significant revenue growth in recent quarters.
    *   Very high profit margins and a recent surge in ROE.
    *   Positive recent earnings surprise.
    *   Relatively low RSI indicating there may be room for price appreciation.

*   **Negatives/Risks:**
    *   Underperformance compared to the S&P 500.
    *   Extremely high MDD values indicating high volatility and risk.
    *   Inconsistent alpha, indicating performance heavily influenced by company-specific factors.
    *   Recent downward trend in stock price, as indicated by SMAs and divergence change.
    *   Hybrid signal giving buy recommendation while other indicators signal short-term decline.
    *   Mixed news sentiment, with articles highlighting both potential and weaknesses.
    *   Wide range in analyst target prices, indicating uncertainty.
    *   High Beta.

*   **Overall:**  TGTX is a high-risk, high-reward stock. The recent financial performance and revenue growth are encouraging, but the historical volatility, underperformance relative to the market, and mixed news sentiment should give investors pause. The potential for large gains is there, but so is the potential for significant losses.

*   **Recommendation:**  Due to the high volatility and mixed signals, a conservative approach is warranted. This is not a "buy and hold" stock for risk-averse investors. Careful monitoring of earnings, clinical trial results, and industry news is essential. Consider a small allocation within a diversified portfolio for investors with a high-risk tolerance who believe in the company's long-term potential.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.